The FDA accepts Cerus' (CERS +5.9%) outline of its Premarket Approval application for the...


The FDA accepts Cerus' (CERS +5.9%) outline of its Premarket Approval application for the INTERCEPT Blood System for platelets which is already in use by customers in 16 countries.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs